Immix Biopharma, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.6
Revenue growth			-100.0%
Cost of goods sold	0.0	0.0	0.0	1.2
Gross profit	0.0	0.0	0.0	-0.6
Gross margin				-100.0%
Selling, general and administrative [+]	4.0	1.2	0.2	0.3
General and administrative	4.0	1.2	0.2	0.3
Research and development	4.2	0.1	0.2
Other operating expenses		-22.8	-0.6
EBITDA [+]	-8.2	21.4	0.1	-0.8
EBITDA growth	-138.4%	17240.6%	-114.7%
EBITDA margin				-144.3%
Depreciation and amortization	0.0	0.0	0.0	0.0
EBIT [+]	-8.2	21.4	0.1	-0.8
EBIT growth	-138.4%	17570.8%	-114.4%
EBIT margin				-144.5%
Non-recurring items		22.8	0.6
Interest expense	0.0	0.2	0.1
Interest expense	0.0	0.2	0.1
Other income (expense), net [+]		-22.8	-0.6	-0.1
Gain (loss) on debt retirement		-0.1
Gain (loss) on derivative instruments		-22.8	-0.6
Other			0.0
Pre-tax income	-8.2	-24.4	-1.1	-1.0
Income taxes	0.0	0.0	0.0	0.0
Net income	-8.2	-24.4	-1.1	-1.0
Net margin				-166.8%

Basic EPS [+]	($0.59)	($6.64)	($0.34)
Growth	-91.1%	1852.1%
Diluted EPS [+]	($0.59)	($6.64)	($0.34)
Growth	-91.1%	1852.1%

Shares outstanding (basic) [+]	13.9	3.7	3.4
Growth	278.1%	8.8%
Shares outstanding (diluted) [+]	13.9	3.7	3.4
Growth	278.1%	8.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.